Over 257 mutations in the human calcium-sensing receptor (hCaSR) gene have been reported. Heterozygous inactivating mutations can result in familial hypocalciuric hypercalcemia (FHH), whereas homozygous inactivating mutations can cause life-threatening neonatal severe hyperparathyroidism (NSHPT). Activating mutations in the hCaSR can result in hypercalciuria and hypocalcemia. A recent publication on the successful treatment of a patient suffering from FHH with the hCaSR positive allosteric modulator cinacalcet prompted our interest in exploring the molecular pharmacology of calcimimetics to correct signaling defects associated with inactivating hCaSR mutations. We prepared 11 mutant hCaSRs, previously identified in patients suffering from NSHPT or FHH, and tested their ability to couple to inositol phosphate accumulation and intracellular calcium mobilization in transiently transfected human embryonic kidney 293 and Chines hamster ovary cells using the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine]. We found that extracellular Ca 2ϩ was significantly less potent on the mutated receptors compared with wild-type hCaSR. However, R-568 was able to enhance the potency of extracellular Ca 2ϩ toward the mutant hCaSRs. Furthermore, R-568 increased the maximal agonist response on several of the mutant CaSRs. We applied a novel operational model of allosteric modulation/agonism that provided a common mechanism to account for the behavior of the wild-type and mutant hCaSRs. The data provide evidence for the potential use of calcimimetics to treat diseases such as FHH and NSHPT where severe hypercalcemia can be lifethreatening.
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was significantly less potent on the mutated receptors compared with wild-type hCaSR. However, R-568 was able to enhance the potency of extracellular Ca 2ϩ toward the mutant hCaSRs. Furthermore, R-568 increased the maximal agonist response on several of the mutant CaSRs. We applied a novel operational model of allosteric modulation/agonism that provided a common mechanism to account for the behavior of the wild-type and mutant hCaSRs. The data provide evidence for the potential use of calcimimetics to treat diseases such as FHH and NSHPT where severe hypercalcemia can be lifethreatening.
The calcium-sensing receptor (CaSR) is a member of the G-protein-coupled receptor family that was originally identified from bovine parathyroid cells and isolated by an expression cloning strategy in Xenopus laevis oocytes . The highest level of expression of the CaSR is found in parathyroid tissue where it plays a crucial role in calcium and phosphate homeostasis. The receptor is also expressed in the thyroid, kidney, brain, stomach, and gastrointestinal tract. Stimulation of the receptor by millimolar concentrations of Ca 2ϩ can activate both G q and G i signaling pathways leading to inositol phosphate production, intracellular Ca 2ϩ flux, and ERK phosphorylation Makita et al., 2007) . In the chief cells of the parathyroid, the CaSR is a negative regulator of parathyroid hormone secretion (PTH) (Brown, 1991) . The CaSR in the C-cells of the thyroid is positively coupled to calcitonin secretion (Fox et al., 1999) . In the kidney, the CaSR and the PTH receptor regulate calcium reabsorption (Chang and Shoback, 2004) . Activation of the receptor in the stomach is associated with increased acid secretion, whereas activation in the gastrointestinal tract has been shown to inhibit fluid secretion from colonic crypt cells (Dufner et al., 2005; Geibel et al., 2006) .
To date, over 257 mutations in the human calcium-sensing receptor (hCaSR) gene have been reported (CaSR database: http://www.casrdb.mcgill.ca/?TopicϭCasrMutation). Inactivating mutations in the hCaSR are responsible for familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) (Pollak et al., 1993) . Heterozygous mutations can cause FHH, whereas the more severe and life-threatening NSHPT is usually caused by a homozygous inactivating mutation in the hCaSR gene. Symptoms of NSHPT include severe hypercalcemia, elevated levels of PTH, hypocalciuria, and osteoporosis. The milder form of the disease, FHH, is often asymptomatic with mild to moderate hypercalcemia and generally normal or slightly elevated levels of PTH. Activating mutations in the hCaSR have also been found, which result in autosomal dominant hypocalcemia with hypercalciuria (Hu et al., 2002) . Recently, a new class of drugs, called calcimimetics, was introduced into the clinic; these compounds are positive allosteric modulators of the hCaSR (Hammerland et al., 1998) . In contrast to calcium, which binds in the venus flytrap extracellular orthosteric domain of the receptor (Silve et al., 2005) , the calcimimetics bind to a region in the transmembrane domain of the hCaSR (Fig. 1A) to increase the receptor's sensitivity to Ca 2ϩ (Petrel et al., 2004) . Calcimimetics have proven to be beneficial to patients suffering from primary and secondary hyperparathyroidism resulting from end-stage renal disease (Goodman et al., 2002) . Both R-568 and cinacalcet are calcimimetics that enhance the activity of Ca 2ϩ at the hCaSR. Patients suffering from secondary hyperparathyroidism, due to end-stage renal disease, who are treated with cinacalcet exhibit a marked reduction in PTH levels and calcium-phosphorus product (Block et al., 2004) .
Our interest in inactivating mutations of the hCaSR was prompted by a recent report in which a 26-year-old male patient was found to suffer from persistent hyperparathyroidism, hypercalcemia, and osteoporosis (Timmers et al., 2006) . The patient was diagnosed with FHH after sequence analysis revealed a heterozygous de novo mutation in which phenylalanine at position 809 was changed to leucine (F809L) in the hCaSR gene. Empirical treatment of the patient with cinacalcet resulted in a reduction in PTH and serum calcium to the normal range. This finding suggests that calcimimetics may have a role in restoring function to mutationally impaired hCaSRs, but to date, there have been very few detailed comparative studies of allosteric modulator actions at clinically relevant hCaSR mutants.
In the current study, we have prepared the F809L mutant hCaSR, along with 10 other mutant hCaSRs that have been described in the literature to cause FHH and NSHPT, and assessed their signaling properties in the absence or presence of R-568 using two different cell-based functional assays. The overall aim of the study was to gain insights into the possible modes by which the mutations may affect allosteric modulation. To this end, we used a novel operational model of allosteric modulation and allosteric agonism (Leach et al., 2007; Aurelio et al., 2009 ) to obtain quantitative estimates of molecular properties underlying the actions of the calcimimetics on the wild-type and mutant hCaSRs. We found that R-568 was able to act as an allosteric agonist as well as a positive allosteric modulator of orthosteric agonist potency and, in some cases, maximal agonist effect, depending on the mutation. Our data also provide support for the potential use of calcimimetics to treat genetic disorders associated with some inactivating mutations in the hCaSR.
Materials and Methods
Chemicals, Plasmids, and Reagents. R-568 was prepared at Amgen, Inc. (Thousand Oaks, CA), and HEK293 cells and CHO cells were obtained from ATCC (Manassas, VA). Yttrium silicate SPA beads and tritiated inositol (50 -80 Ci/mmol) were obtained from GE Healthcare (Chalfont St. Giles, UK). pcDNA3.1-Aequorin and pcDNA3.1-hCaSR were prepared by standard cloning techniques. Mutant hCaSRs were prepared using QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Mutations were confirmed by automated DNA sequencing. Plasmids were prepared with a QIAGEN plasmid mega DNA preparation kit (QIAGEN, Inc., Chatsworth, CA).
Aequorin Assay. Six million CHO cells were seeded in a 150-cm 2 dish in Dulbecco's modified Eagle's medium/F-12/10% fetal calf serum without antibiotics. One hour after plating, the cells were transfected with 10 g of receptor plasmid and 10 g of aequorin plasmid with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the binding) site, putative allosteric modulator binding site (green ellipse), regions harboring the mutations investigated in the current study, and the molecular parameters governing the allosteric interaction between the orthosteric, allosteric and G-protein coupling sites (blue). B, a reaction network describing the interaction of hCaSR (denoted R) with extracellular Ca 2ϩ (denoted A) and R-568 (denoted B) is shown. Occupancy of the RA complex and RB complex is governed by dissociation constants K A and K B , respectively; occupancy of the RAB tertiary complex is governed by dissociation constants K A , K B , and cooperativity factor ␣. Each receptor ligand complex can impart a stimulus upon the cell denoted S A , S B , and S AB that is proportional to the receptor occupancy. The total cellular response, denoted E, is the sum of the stimuli that is processed through a logistic function that takes into account the nonlinear relationship between receptor occupancy and response. Efficacy modulation is defined by the parameter ␤, which is the ratio of S AB /S A . Further details of the model can be found under Appendix.
manufacturer's instructions. The cells were incubated at 37°C, 5% CO 2 for 6 h, and the medium was replaced. One day after transfection, the cells were detached by brief treatment with trypsin/EDTA, washed and resuspended in 10 ml of HBSS containing 0.5 mM CaCl 2 and 0.1% BSA. Coelenterazine F was added to a final concentration of 1 g/ml. The cells were gently agitated every 15 min for a total of 2 h. The cells were then diluted 3-fold in the same buffer lacking coelenterazine F. R-568 was prepared as a 100ϫ stock in dimethyl sulfoxide. Just before the assay, the R-568 was diluted in 100 l of calcium-free HBSS with 0.1% BSA and placed in a 96-well white plate (Corning Life Sciences, Lowell, MA). One hundred microliters of cells were then added to the plate on a MicroLumat luminometer (Berthold Technologies, Oak Ridge, TN), and the luminescence was recorded over a time of 20 s. The lowest concentration of calcium tested was 0.25 mM.
Inositol Phosphate Accumulation Assay. HEK293 cells were dispensed into a poly-D-lysine tissue, culture-treated 96-well plate at a density of 25,000 cells per well. The next day, the cells (ϳ80 -90% confluent) were transfected with 100 ng of receptor plasmid per well using Lipofectamine 2000 according the manufacturer's instructions. Six hours after transfection, the medium was replaced with inositolfree Dulbecco's modified Eagle's medium/10% dialyzed fetal calf serum supplemented with 1 Ci/ml tritiated inositol. After incubation overnight, the cells were washed once in calcium-free HBSS and then treated with the 100 l of calcium-free HBSS/0.01% BSA containing various concentrations of CaCl 2 , R-568 (prepared as above in dimethyl sulfoxide), and 10 mM LiCl and incubated at 37°C for 1 h. The medium was aspirated, and the cells were lysed with ice-cold 20 mM formic acid. After incubation at 4°C for 5 h, the lysate was added to yttrium silicate scintillation proximity assay beads, allowed to settle overnight, and read on a Beckman TopCount scintillation counter (Beckman Coulter, Fullerton, CA).
Immunoblotting. HEK293 cells were transfected with 10 g of wild-type or mutant CaSR plasmid DNA in a 150-cm 2 flask using Lipofectamine 2000. Twenty-four hours later, the cells were detached from the plate using Ca 2ϩ /Mg 2ϩ -free phosphate-buffered saline containing 0.5 mM EDTA. The cells were spun down and quickfrozen in liquid nitrogen. The cell pellets were thawed on ice, dounced, and gently spun at 1000 rpm on a tabletop centrifuge to remove debris. The supernatant was then ultracentrifuged at 100,000g for 1 h. The membrane pellet was resuspended in phosphate-buffered saline, and protein concentration was determined using a BCA protein assay kit (Pierce, Rockford, IL). Approximately 10 g of membrane protein was dissolved in SDS sample buffer and separated on a 7.5% SDS-polyacrylamide gel electrophoresis gel. The proteins on the gel were transferred to a nitrocellulose membrane and incubated with a monoclonal anti-calcium-sensing receptor antibody at a dilution of 1:800 (Clone HL 1499; Sigma-Aldrich, St. Louis, MO). The membrane was then incubated with a secondary goat anti-mouse antibody conjugated to horseradish peroxidase at a dilution of 1:10,000. After extensive washing, the hCaSR protein was detected using the Super Signal West Pico chemiluminescent substrate (Pierce).
Data Analysis. Figure 1A illustrates conceptually the relationship between the orthosteric (N-terminal) and allosteric (transmembrane) domains of the hCaSR, as well as indicating the location of the mutations investigated in the current study. This figure also highlights the molecular properties (blue) that govern the interaction between orthosteric ligand (e.g., Ca 2ϩ ) and allosteric modulator (e.g., R-568 or cinacalcet) and G-protein. Figure  1B shows the mass action reaction network describing this interaction. A comprehensive description of the model can be found under the Appendix. In brief, receptor occupancy is governed by the dissociation constant of each ligand to its site on the receptor (K A for orthosteric ligand, A; K B for allosteric modulator, B) and the magnitude of the allosteric effect that each ligand exerts on the binding affinity of the other, quantified by the binding cooperativity factor (␣); positive binding cooperativity (␣ Ͼ 1) results in an increase in affinity of the orthosteric ligand when the receptor is occupied by the allosteric ligand and vice versa. Stimuli, denoted S, are defined as being directly proportional to the concentration of the ligand-bound receptor. Hence, the quantification of stimuli is linearly related to the occupancy of R by each ligand. The summation of the stimuli imparted by the RA, RB, and RAB complexes (denoted as S A , S B , and S AB , respectively) is processed through a transducer function that accounts for nonlinear amplification of the total stimulus. The cellular response to ligand stimulation is denoted E. Allosteric ligands lacking intrinsic signaling efficacy (i.e., agonism) do not impart any stimulus upon the receptor; hence, S B ϭ 0. We define ␤ as the ratio of the stimuli of the RAB complex to the RA complex, S AB /S A , in essence, a measure of the allosteric effect of the modulator on the signaling efficacy of the orthosteric agonist over and above any effects the modulator has on the binding affinity of the agonist (see Appendix) (Leach et al., 2007; Aurelio et al., 2009) . For values of ␤ Ͼ 1, the agonist efficacy is increased relative to the orthosteric ligand bound to the receptor alone. For values of ␤ Ͻ 1, the allosteric ligand decreases the efficiency of orthosteric ligand/receptor/G-protein coupling. Finally, to operationally quantify direct agonistic effects of orthosteric and allosteric ligands, respectively, the parameters, A and B are used; these parameters incorporate the influence of receptor density and stimulus-response amplification (Leach et al., 2007) ; the larger the value, the greater the cellular response elicited by the agonist.
Data from the wild-type hCaSR and from mutant hCaSRs at which R-568 showed no enhancement of orthosteric agonist maximal response (R62M, F881L, P55L, R227Q, and R227L; see Results), were fitted via nonlinear regression using GraphPad Prism 4.01 to the following form of our operational model of allosterism/agonism (see Appendix) (see supplementary information for derivation in Aurelio et al., 2009 ):
where E denotes effect, E m denotes the maximal possible cellular response, EC 50A denotes the half-maximal response of orthosteric full agonist A, n denotes a logistic slope factor that links occupancy to observed response, B denotes efficacy of RB, and all other parameters are as defined above. This analysis assumes that Ca 2ϩ is a full agonist in the systems under investigation, and thus, any positive allosteric modulation of either its affinity or efficacy will manifest only as changes in its potency, not maximal agonist effect. As a consequence, analysis using this equation cannot provide individual estimates of ␣ and ␤ factors but does yield a composite cooperativity parameter (␣␤) that quantifies the overall allosteric effect of the modulator on the orthosteric ligand.
Modeling of mutant hCaSRs in which Ca 2ϩ acted as a partial agonist and R-568 showed an enhancement of orthosteric agonist maximal effect (mutants F809L, R185Q, F180C, Y218C, and P39A) was performed using the following expanded operational model of allosterism agonism (see Appendix) (Leach et al., 2007) :
where A denotes efficacy of RA. Where appropriate, individual concentration-response curves were also fitted empirically to a variable slope Hill equation by nonlinear regression analysis using Prism 4.01 (GraphPad Software Inc., San Diego, CA). In all instances, measures of potency, affinity, cooperativity, and efficacy were estimated as base 10 logarithms (Christopoulos, 1998) .
Results
Plasmids encoding the wild-type and mutant hCaSRs were transiently transfected into HEK293 cells, and cell membranes were isolated to assess protein expression. Western blot analysis with an anti-hCaSR monoclonal antibody detected the wildtype hCaSR as well as all 11 mutant receptors (Fig. 2) . The main band was located at ϳ150 kDa, and in some cases, a higher band at ϳ230 kDa was detected. This result is similar to a previous report (Hauache et al., 2000) .
Functional activation of the wild-type and mutant hCaSRs was quantified by measuring intracellular Ca 2ϩ flux using the photoprotein aequorin and by inositol phosphate (IP) accumulation. Shown in Table 1 are the log EC 50 and E max values for the wild-type hCaSR and mutant receptors in both the aequorin and IP assays. All 11 of the mutant receptors displayed reduced potency to extracellular Ca 2ϩ compared with the wild-type hCaSR; three of the mutants, R185Q, F180C, and Y218C, had log EC 50 values greater than Ϫ1.2 (i.e., EC 50 Ͼ 60 mM) in the aequorin assays. In addition, several of the mutants (F809L, R185Q, F180C, Y218C, P39A, and L13P) displayed a blunted maximal agonist response compared with the wild-type hCaSR. It should be noted that the concentration-response curves for signaling via the hCaSR are routinely characterized by Hill coefficients ranging from 2 to 4, which is steeper than those of other G-protein-coupled receptors for similar pathways (Huang et al., 2009) . Thus, at physiologically relevant serum Ca 2ϩ levels, even a small change in the extracellular Ca 2ϩ concentration in hCaSR expressing cells will result in a large change in cellular response.
We then investigated the extent to which the calcimimetic R-568 could 1) modulate the potency of the mutant hCaSRs to extracellular Ca 2ϩ and 2) affect the E max values of the mutant hCaSRs that displayed a blunted maximal response to extracellular Ca 2ϩ . To facilitate interpretation of the calcimimetic effects, we applied an operational model of allosteric modulation/agonism to the data.
As shown in Fig. 3 , the wild type receptor displayed a robust response to orthosteric agonist in both the Ca 2ϩ flux and IP accumulation assays. In both assays, the effect of R-568 was characterized by an increase in basal responsiveness and an enhancement of the potency of extracellular Ca 2ϩ ; no significant effects were noted upon orthosteric agonist E max . This latter finding is consistent with extracellular Ca 2ϩ being a full agonist at the wild-type hCaSR, such that the maximal cellular response attainable for that particular signaling pathway is already achieved. Global fitting of the entire family of curves to the operational model of allosterism (eq. 1) yielded the estimates of orthosteric agonist potency (log EC 50 ), modulator affinity (log K B ), modulator efficacy (log B ), and cooperativity (log ␣␤) shown in Table 2 . From this analysis, it can be seen that R-568 is not only an allosteric modulator but an allosteric partial agonist in both assay formats because its values were greater than 0. In addition, R-568 clearly displayed positive cooperativity in both the IP assay and aequorin assay (log ␣␤ ϭ 0.65 and 0.43, respectively), although we could not ascertain to what extent this reflected affinity modulation relative to signaling (efficacy) modulation.
Similar to the wild type hCaSR, 5 of the 11 mutant hCaSRs examined (R62M, F881L, P55L, R227Q, and R227L) exhibited an unaltered maximal agonist response to extracellular Ca 2ϩ in both aequorin and IP assays (Fig. 4) . This indicates that extracellular Ca 2ϩ retains its ability to act as a full agonist at these five mutant receptors. However, there was a marked reduction in orthosteric agonist potency at the mutants compared with the wild-type hCaSR ( Table 1 ), suggesting that either Ca 2ϩ affinity and/or signaling efficacy has been reduced to some extent by the mutation. R-568 retained the ability to act as a positive allosteric modulator on all of the mutant hCaSRs, manifested as a potentiation of orthosteric agonist potency, but showed substantially reduced direct agonistic effects on basal system responsiveness. Global fitting of the concentration-response data to eq. 1 yielded the operational parameter estimates shown in Table 2 , where it can be seen that the log B values of R-568 as an allosteric agonist were significantly reduced at each of the mutants relative to the wild-type receptor. Given that the activity of the orthosteric agonist is also impaired at these mutations, this suggests that the mutated residues are important for generating an active conformation that is common to both orthosteric and allosteric agonists. Importantly, application of our model also allowed for the direct determination of the affinity (log K B ) of R-568 at the wild-type and mutant hCaSRs. In general, none of the five mutations had a substantial effect on the binding affinity of the modulator; a modest, albeit significant, increase in affinity was noted from the analysis of the aequorin data, but not the inositol phosphate data, at the R227Q/L mutations. The relative insensitivity of the affinity of the modulator to these five mutations is consistent with the fact that none of them is predicted to be in the key transmembrane regions that comprise the allosteric pocket for phenylalkylamine hCaSR modulators. Finally, the analysis also yielded estimates of the overall cooperativity (log ␣␤) between Ca 2ϩ and R-568 at the mutant receptors. Within assays, there was no significant difference in the positive cooperativity displayed at each of the mutants compared with the wild type, with the exception of F881L in the aequorin assay (Table 2) where a modest increase was noted. Collectively, the results of this analysis indicate that the affinity of R-568 and its ability to allosterically modulate Ca 2ϩ are quantitatively similar at each of the five mutants and the wild type hCaSR.
In contrast, the six other mutations we investigated Log K B is the logarithm of the equilibrium dissociation of R-568 at the free receptor; log EC 50 is the logarithm of the potency of extracellular Ca 2ϩ in absence of R-568; log B is the logarithm of the efficacy of R-568 at the free receptor; log ␣␤ is the logarithm of the composite cooperativity factor; and ␣␤ is the antilogarithm (mean) of the composite cooperativity factor with the range in parentheses based on estimated log ␣␤ values. Parameter values were obtained using eq. P value Ͻ0.01 one-way analysis of variance followed by Dunnett's post-test. P value Ͻ0.05 one-way analysis of variance followed by Dunnett's post-test. * Significantly different from wild-type hCaSR, P value Ͻ0.01 one-way analysis of variance followed by Dunnett's post-test. ** Significantly different from wild-type hCaSR, P value Ͻ0.05 one-way analysis of variance followed by Dunnett's post-test.
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at ASPET Journals on June 9, 2017 jpet.aspetjournals.org Downloaded from (F809L, R185Q, F180C, Y218C, P39A, and L13P) resulted in an obvious blunting of the maximal orthosteric agonist effect, such that Ca 2ϩ behaved as a partial agonist (Fig. 5) . The partial agonist activity that Ca 2ϩ displayed with these mutant hCaSRs made the analysis of the data more complex but also afforded an opportunity to explore the potential contribution of affinity modulation (i.e., ␣ in the operational model) relative to efficacy modulation (i.e., ␤ in the operational model) on the actions of the calcimimetic at these mutations; only changes in the ␤ parameter would be expected to modify the maximal responsiveness to extracellular Ca 2ϩ when the orthosteric ligand is a partial agonist. Indeed, this was observed with all six mutant hCaSRs when treated with R-568. In both the aequorin and IP assays, each of the mutants displayed an R-568 concentration-dependent increase in both extracellular Ca 2ϩ agonist potency and maximal response. Although the ability of R-568 to act as an allosteric agonist was virtually abolished at these mutations, the pronounced functional rescue of Ca 2ϩ signaling indicated that the modulator was still able to bind to the allosteric site on the receptor to modulate the activity of the orthosteric agonist. Thus, in agreement with the mutations that did not affect maximal Ca 2ϩ responsiveness, it is likely that the six mutants shown in Fig. 5 also have a minimal effect on the allosteric modulator binding pocket. -fold increase in orthosteric agonist maximal response (E2/ E1) in the presence of the highest concentration of R-568 used. The calcimimetic had the largest effect upon mutants R185Q, Y218C, and F180C. In the aequorin assay, the log EC 50 values were greater than Ϫ1.22 (60 mM) for each of these three mutants. Treatment with 33 M R-568 increased agonist potency of R185Q, Y218C, and F180C to log EC 50 ϭ Ϫ2.06, Ϫ1.92, and Ϫ2.12, respectively. In addition, maximal agonist effect was increased by 7-to ϳ10-fold by the addition of 33 M R-568 for these three mutant hCaSRs. In the case of F809L, P39A, and L13P mutant hCaSRs, treatment with 33 M R-568 induced an increase in orthosteric agonist potency by 7-, 5-, and 3.6-fold, respectively. There was an increase in maximal agonist effect by 1.4-, 1.5-, and 1.6-fold, respectively. In the IP assay, the effect of 33 M R-568 upon the maximal agonist response was greatest for mutants F809L, R185Q, F180C, and Y218C (2.4-, 1.8-, 2.7-, and 3.3-fold, respectively). These four mutant hCaSRs exhibited a 2.3-to 5.6-fold increase in orthosteric agonist potency as well. For mutant P39A hCaSR, R-568 did cause a significant increase in orthosteric agonist potency; however, the effect upon maximal agonist response did not reach significance. For mutant L13P, the effect of R-568 upon potency and response did not reach statistical significance.
In contrast to the mutant hCaSRs in which extracellular Ca 2ϩ was a full agonist, we were not able to fit the experimental data in Fig. 5 to our global allosteric model due to the large number of parameters in eq. 2 and the limited definition of the control orthosteric agonist curve in the aequorin assay. Instead, we performed simulations using eq. 2 to explore possible mechanisms that would be consistent with the observed experimental findings. Figure 6A shows simulations of the effect of R-568 on the wild-type hCaSR where extracellular Ca 2ϩ is assumed to act as a full agonist. When ␣ and ␤ equal 1 (no cooperativity or efficacy enhancement), the only factor affecting the Ca 2ϩ concentration-response curves is the direct allosteric agonist effect of R-568, as proven by the slight increase in basal activity in the simulated Ca 2ϩ concentration-response curve. When ␣ is increased from 1 to 5 (Fig. 6B ) while maintaining ␤ ϭ 1, a potentiation of extracellular Ca 2ϩ potency is observed without any effect upon maximal agonist response. The larger the value of ␣, the more the concentration-response curve shifts to the left. The change in concentration-response curve location is saturable because the maximal effect that R-568 can exert occurs when the receptor is fully occupied by R-568 and is governed by the value of ␣. An increase in potency of extracellular Ca 2ϩ is also observed when ␤ is increased from 1 to 5 while maintaining neutral binding cooperativity (␣ ϭ 1; Fig. 6C) . Again, the effect is saturable because the maximal effect that R-568 can exert upon the Ca 2ϩ concentration response occurs when the receptor is fully occupied by R-568. Thus, when extracellular Ca 2ϩ is a full agonist, positive allosteric effects of ␣ and ␤ are indistinguishable, hence our inability to individually estimate the two parameters from experiment (Fig. 3) . However, the composite parameter, ␣␤, was obtainable. In contrast, the situation changes when the orthosteric ligand is a partial agonist, as is the case for several of the mutant hCaSRs that we examined. Figure 6D shows the theoretical effect of R-568 upon a mutant hCaSR in which Ca 2ϩ is a partial agonist, i.e., is characterized by a low A value such that maximal system responsiveness is not achieved at maximal receptor occupancy by the orthosteric ligand. In this situation, when ␣ and ␤ equal 1, the resulting concentration-response curves are similar in profile to the fullagonist situation (Fig. 6A) , with the exception that the maximal response that Ca 2ϩ can attain is only substantially below the E max . An increase in ␣ from 1 to 5 (Fig. 6E) , while maintaining ␤ ϭ 1, results in a potentiation of extracellular Ca 2ϩ potency without an increase in E max , because the allosteric effect is only on orthosteric ligand affinity. However, increasing ␤ from 1 to 5 while maintaining ␣ ϭ 1 (Fig. 6F ) results in both an increase in orthosteric agonist potency and maximal response. In fact, the modest increase in ␤ results in the orthosteric ligand behaving as a full agonist in the presence of R-568. Hence, ␣ only affects potency, whereas ␤ can affect both potency and efficacy when the orthosteric ligand is a partial agonist. It is clear from the data presented in Fig. 5 that ␤ is greater than 1 for R-568 acting upon mutants F809L, R185Q, F180C, Y218C, P39A, and L13P. Furthermore, R-568 has a slight agonist activity in the aequorin assay for mutants F809L, R185Q, and F180C, which is consistent with the efficacy ( B ) between 0 and 1. Furthermore, assigning a value of ␤ greater than 1 adequately describes the behavior of R-568 on the mutant receptors shown in Fig. 4 where extracellular Ca 2ϩ is a full agonist, without the need to invoke any effect on orthosteric ligand affinity (␣ effect). Of course, combinations of ␣ Ͼ 1 and ␤ Ͼ 1 could give the same result, but the most parsimonious explanation of the effects of R-568 upon the wild-type and all of the mutant hCaSRs is that R-568 acts predominantly, if not exclusively, as an efficacy modulator at the hCaSR.
Discussion
Inactivating mutations in the hCaSR have been shown to cause FHH and NSHPT (Pollak et al., 1993) . Treatments of these illnesses involve counteracting the effects of elevated levels of PTH (Miyashiro et al., 2004) . Recently, cinacalcet was to the receptor). Simulations were performed using eq. 2 as described under Materials and Methods. To determine the effects of the mutant hCaSRs that showed a blunted response to extracellular Ca 2ϩ , a value of 1 was assigned to A to model extracellular Ca 2ϩ acting as a partial agonist that achieves 50% of the maximal agonist response.
shown to be an effective therapy for the treatment of a patient suffering from a heterozygous de novo inactivating mutation in the hCaSR in which phenylalanine at position 809 was replaced by leucine (Timmers et al., 2006) . The patient harboring this mutation presented symptoms of hypercalcemia, elevated PTH, osteoporosis, and recurrent psychosis. Normalization of serum calcium and PTH levels was sustained by a twice-daily oral dose of cinacalcet. We found that R-568, a first-generation calcimimetic and a precursor to cinacalcet, had a significant effect upon the F809L mutant hCaSR, increasing the potency of extracellular Ca 2ϩ as well as enhancing its signaling efficacy in both aequorin and IP assays. Hence, our in vitro data are consistent with the in vivo efficacy observed in the patient treated with cinacalcet and suggest a possible underexploited role for calcimimetics in restoring function to mutationally impaired hCaSRs in a clinical setting.
It is important to note that our study represents the first time that an exploratory model of allosteric modulation and agonism has been applied in trying to rationalize the mechanistic basis of calcimimetic actions at the hCaSR. Our finding that R-568 is able to restore function to all mutations that we investigated could be adequately reconciled with a model whereby the modulator exerts its predominant effect on the signaling efficacy (␤), rather than the affinity (␣), of the orthosteric ligand. This hypothesis is also consistent with the finding that the direct agonistic effects of the allosteric ligand were also markedly reduced ( Fig. 4; Table 2 ) or abolished (Fig. 5) at each of the loss-offunction mutations; if the mechanism of action of a modulator is to promote a state of the receptor that displays increased signaling efficiency, then mutations that perturb the ability of the receptor to adopt such an active signaling state would also be expected to impair the ability of the modulator to promote that state. Furthermore, the fact that we were able to directly fit the model to the experimental data for the wild type and five of the mutant receptors allowed direct conclusions to be made about the affinity of the modulator for the allosteric site on the hCaSR. Namely, none of the mutations had a substantial affect on R-568 affinity, which is consistent with them being located outside of the modulator binding pocket. It is possible that other mutations occurring closer or within the putative allosteric binding domain in the transmembrane bundle may have a profound effect on modulator affinity and hence clinical effectiveness but may not necessarily manifest as loss-of-function mutations for the orthosteric ligand. Thus, studies such as those described herein may prove vital in differentiating such possibilities at the molecular level.
It should also be acknowledged that allosteric models such as that utilized herein contain many parameters and may not always prove amenable to routine concentration-response curve analysis; such was the instance for the mutational data shown in Fig. 5 . However, even in the latter situation, the models can at least be used heuristically to understand possible ligand, receptor, and system properties that may lead to the observed patterns of behavior (Fig. 6) . Another complication that is specific to the hCaSR is that this receptor is a homodimer; our operational model was designed to address cases in which the receptor exists as dimer of identical mutant hCaSR polypeptides and not a heterodimer of the wildtype polypeptide and mutant hCaSR polypeptide (Brown, 2005) . Therefore, our allosteric model is perhaps most applicable to cases involving NSHPT where the patient usually harbors a homozygous inactivating mutation in the hCaSR gene.
In addition to the mechanistic insights provided by our analysis, there are possible clinical implications to this study. For instance, we found that R-568 was able to potentiate orthosteric agonist potency and maximal agonist response of F809L, R185Q, F180C, P39A, Y218C, and L13P mutant hCaSRs that have been described in the literature (Aida et al., 1995; Heath et al., 1996; Bai et al., 1997; Chikatsu et al., 1999; Cetani et al., 2003; Miyashiro et al., 2004; Timmers et al., 2006; Zajickova et al., 2007) . It is interesting to note that the L13P mutation occurs in the 19 amino acid signal peptides of the hCaSR. Recently, it was reported that the L13P mutant showed reduced cell surface expression in HEK293 cells, perhaps as a result of the mutation interfering with the function of the signal peptide to properly insert into endoplasmic reticulum . This finding is consistent with our result showing a reduced response of the L13P mutant to extracellular Ca 2ϩ challenge in both the aequorin and IP assays. It is interesting that it has recently been shown that when R-568 was added to an overnight culture of HEK293 cells transfected with cDNAs encoding mutant hCaSRs, an enhancement of cell surface expression was observed (Huang and Breitwieser, 2007) . Five of the mutant receptors studied (R227Q, R227L, R62M, F881L, and P55L) displayed a response comparable to the wild-type hCaSR when challenged with extracellular Ca 2ϩ but a reduction in potency (Chou et al., 1995; Pearce et al., 1996; Carling et al., 2000; Wystrychowski et al., 2005) . Our results reveal that R-568 significantly increased the potency of each of these mutant hCaSRs when transiently expressed in HEK293 and CHO cells. Fitting of the data to an operational model of allosteric agonism revealed that the affinity (log K B ) and cooperativity (log ␣␤) of R-568 to these five mutant receptors was similar to the wild-type hCaSR, whereas R-568 displayed a significantly reduced allosteric agonist efficacy (log B ). The findings presented here suggest that calcimimetics may potentially be of use to patients in correcting the defects caused by the mutant hCaSRs described in this study.
In summary, we have shown that the calcimimetic R-568 acts as a positive allosteric modulator on 11 mutant hCaSR constructs that have been identified in the patient population to cause FHH and NSHPT. In addition, R-568 enhanced the maximal agonist response of 6 mutants of the 11 hCaSRs evaluated in this study. Furthermore, additional reports demonstrate that R-568 has a positive effect on other hCaSR mutations that have been described in the patient population (Hauache et al., 2000; Rus et al., 2008) . We have presented an allosteric model that adequately predicts the behavior of R-568 on the mutant hCaSRs that we studied and indicates that it acts as a signaling efficacy modulator. Currently, patients afflicted with NSHPT are treated with bisphosphonates. This treatment has limited efficacy and does not specifically address the problem of abnormal hCaSR function. There is an unmet medical need for treatment of NSHPT. Our results suggest that further research on the treatment of patients harboring inactivating mutations in the hCaSR with calcimimetics is warranted. Reduction of serum calcium and PTH upon drug delivery should be rapid (within hours), and measurement of drug efficacy can be quickly accessed in patients.
Derivation of the Formula for the Effect (Equation 3
). The equilibrium concentrations are related through the dissociation constants and the cooperativity factor:
where is the fraction of free receptor at equilibrium. The individual stimuli are given below:
For the total stimulus, we have
The effect is given by
We already have from eq. 11 an expression for S/(K s ) to be substituted into eq. 12. We next found an expression for 1/ also to be substituted in eq. 12.
Using the conservation of the receptor R, we have:
Thus,
We substituted into the expression of E/E m from eq. 12 the expressions of S/(K s ) and 1/ from eqs. 11 and 14. We obtain
By multiplying by (K A K B ) n the numerator and the denominator of the main fraction in the right side of eq. 15, we obtain the following equivalent expression:
Equation 16 is precisely eq. 3, as proven. In eq. 16, we introduce the parameter ␤ ϭ ( AB )/( A ). We obtain
Equation 17 is eq. 2 as presented under Materials and Methods.
Simplification of the Equation 3
When A is a Full Agonist. According to the operational model of agonism (Black and Leff, 1983) , we have 
We again used the approximation A Ͼ Ͼ1 to discard the remaining occurrences of A . We obtain
By simple rearrangements of terms, this is equivalent to
Equation 22 is eq. 1 as presented under Materials and Methods.
